This CPB is revised to state that bortezomib is considered medically necessary for lymphoplasmacytic lymphoma and as second-line treatment for mycosis fungoides. These policy revisions are supported by guidelines from the National Comprehensive Cancer Network. This CPB has been revised to state that bortezomib is considered experimental and investigational for the treatment of osteosarcoma and antibody-mediated rejection.